Coherus Biosciences | CHRS - Gross Profit On Sales


Coherus Biosciences reported $4.95M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 22.21M 28.15M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Baxter International USD 577M 373M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Fujifilm JPY 347.51B 14.74B Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Merck USD 13.42B 431M Sep/2025
Myriad Genetics USD 143.8M 8M Sep/2025
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xencor USD 21M 22.61M Sep/2025
Zoetis USD 1.64B 73M Dec/2025